首页 > 最新文献

Digestive and Liver Disease最新文献

英文 中文
Impact of graft-to-recipient weight ratio on early systemic inflammatory response syndrome risk following pediatric liver transplantation 移植物与受体体重比对儿童肝移植术后早期全身性炎症反应综合征风险的影响
IF 4 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.dld.2024.11.015
Alaita Fatima Bakhtiari , Aqsa Sabir
None
没有。
{"title":"Impact of graft-to-recipient weight ratio on early systemic inflammatory response syndrome risk following pediatric liver transplantation","authors":"Alaita Fatima Bakhtiari ,&nbsp;Aqsa Sabir","doi":"10.1016/j.dld.2024.11.015","DOIUrl":"10.1016/j.dld.2024.11.015","url":null,"abstract":"<div><div>None</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 2","pages":"Pages 647-648"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author's reply: “Impact of graft-to-recipient weight ratio on early systemic inflammatory response syndrome risk following pediatric liver transplantation” 作者回复:“移植物与受体体重比对儿童肝移植术后早期系统性炎症反应综合征风险的影响”。
IF 4 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.dld.2024.12.006
Junshan Long , Chunqiang Dong
{"title":"Author's reply: “Impact of graft-to-recipient weight ratio on early systemic inflammatory response syndrome risk following pediatric liver transplantation”","authors":"Junshan Long ,&nbsp;Chunqiang Dong","doi":"10.1016/j.dld.2024.12.006","DOIUrl":"10.1016/j.dld.2024.12.006","url":null,"abstract":"","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 2","pages":"Pages 649-650"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142827474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fairness and pitfalls of the Italian waiting list for elective liver transplantation: The ECALITA registry study 意大利择期肝移植候选名单的公平性和隐患:ECALITA 登记研究。
IF 4 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.dld.2024.08.039
Tommaso Maria Manzia , Silvia Trapani , Alessandra Nardi , Andrea Ricci , Ilaria Lenci , Bruno Sensi , Roberta Angelico , Tullia Maria De Feo , Salvatore Agnes , Enzo Andorno , Umberto Baccarani , Amedeo Carraro , Matteo Cescon , Umberto Cillo , Michele Colledan , Domenico Pinelli , Luciano De Carlis , Paolo De Simone , Davide Ghinolfi , Fabrizio Di Benedetto , Mario Angelico

Background

The challenge of transplant waiting-lists is to provide organs for all candidates while maintaining efficiency and equity.

Aims

We investigated the probability of being transplanted or of waiting-list dropout in Italy.

Methods

Data from 12,749 adult patients waitlisted for primary liver-transplantation from January 2012 to December 2022 were collected from the National Transplant-Registry.The cohort was divided into Eras:1 (2012–2014);2 (2015–2018);and 3 (2019–2022).

Results

The one-year probability of undergoing transplant increased (67.6 % in Era 1vs73.8 % in Era 3,p < 0001) with a complementary 46 % decrease in waiting-list failures. Patients with hepatocellular-carcinoma were transplanted more often than cirrhotics[at model for end-stage liver-disease (MELD)-15:HR = 1.28,95 %CI:1.21–1.35;at MELD-25:HR = 1.04,95 %CI:0.92–1.19) and those with other indications (at MELD-15:HR = 1.27,95 %CI:1.11–1.46) across all eras. Candidates with Hepatitis-B-virus (HBV)related disease had a greater probability of transplant than those with Hepatitis-C virus-related (HR = 1.13,95 %CI:1.07–1.20), alcohol-related (HR = 1.13,95 %CI:1.05–1.21), and metabolic-related (HR = 1.18,95 %CI:1.09–1.28)disease. Waiting-list failures increased by 27 % every 5 MELD-points and by 14 % for every 5-year increase in recipient-age and decreased by 10 % with each 10-cm increase in stature. Blood-group O patients showed the highest probability of waiting-list failure (HR = 1.28,95 %CI:1.15–1.43).

Conclusions

Liver-transplantation waiting-list success-rates have significantly improved in Italy, with patients with hepatocellular-carcinoma and/or HBV-related diseases being favored. High MELD-score, old-age, short-stature, and blood-group O were significant risk-factors for waiting-list failure. Efforts to improve organ-allocation and prioritization-policies are underway.
背景:移植候选名单面临的挑战是在保持效率和公平的前提下为所有候选者提供器官:移植候选名单面临的挑战是在保持效率和公平的同时为所有候选者提供器官。目的:我们调查了在意大利被移植或退出候选名单的概率:方法:从国家移植登记处收集了2012年1月至2022年12月期间12749名等待初次肝移植的成年患者的数据,并将队列分为1期(2012-2014年)、2期(2015-2018年)和3期(2019-2022年):结果:一年后接受移植的概率增加了(第 1 个时代为 67.6%,第 3 个时代为 73.8%,P < 0001),同时等待名单上失败的患者也减少了 46%。在所有时代,肝细胞癌患者比肝硬化患者[在终末期肝病模型(MELD)-15:HR = 1.28,95 %CI:1.21-1.35;在MELD-25:HR = 1.04,95 %CI:0.92-1.19]和其他适应症患者(在MELD-15:HR = 1.27,95 %CI:1.11-1.46)更多接受移植。与乙型肝炎病毒(HBV)相关疾病的候选者比丙型肝炎病毒相关疾病(HR = 1.13,95 %CI:1.07-1.20)、酒精相关疾病(HR = 1.13,95 %CI:1.05-1.21)和代谢相关疾病(HR = 1.18,95 %CI:1.09-1.28)的候选者有更大的移植几率。MELD积分每增加5分,等待名单上的失败者就会增加27%;受者年龄每增加5岁,失败者就会增加14%;身材每增加10厘米,失败者就会减少10%。O血型患者出现等待失败的概率最高(HR = 1.28,95 %CI:1.15-1.43):结论:在意大利,肝移植等待成功率已显著提高,肝细胞癌和/或 HBV 相关疾病患者更受青睐。MELD评分高、年龄大、身材矮小和O型血是导致候诊失败的重要风险因素。目前正在努力改进器官分配和优先排序政策。
{"title":"Fairness and pitfalls of the Italian waiting list for elective liver transplantation: The ECALITA registry study","authors":"Tommaso Maria Manzia ,&nbsp;Silvia Trapani ,&nbsp;Alessandra Nardi ,&nbsp;Andrea Ricci ,&nbsp;Ilaria Lenci ,&nbsp;Bruno Sensi ,&nbsp;Roberta Angelico ,&nbsp;Tullia Maria De Feo ,&nbsp;Salvatore Agnes ,&nbsp;Enzo Andorno ,&nbsp;Umberto Baccarani ,&nbsp;Amedeo Carraro ,&nbsp;Matteo Cescon ,&nbsp;Umberto Cillo ,&nbsp;Michele Colledan ,&nbsp;Domenico Pinelli ,&nbsp;Luciano De Carlis ,&nbsp;Paolo De Simone ,&nbsp;Davide Ghinolfi ,&nbsp;Fabrizio Di Benedetto ,&nbsp;Mario Angelico","doi":"10.1016/j.dld.2024.08.039","DOIUrl":"10.1016/j.dld.2024.08.039","url":null,"abstract":"<div><h3>Background</h3><div>The challenge of transplant waiting-lists is to provide organs for all candidates while maintaining efficiency and equity.</div></div><div><h3>Aims</h3><div>We investigated the probability of being transplanted or of waiting-list dropout in Italy.</div></div><div><h3>Methods</h3><div>Data from 12,749 adult patients waitlisted for primary liver-transplantation from January 2012 to December 2022 were collected from the National Transplant-Registry.The cohort was divided into Eras:1 (2012–2014);2 (2015–2018);and 3 (2019–2022).</div></div><div><h3>Results</h3><div>The one-year probability of undergoing transplant increased (67.6 % in Era 1<em>vs</em>73.8 % in Era 3,<em>p</em> &lt; 0001) with a complementary 46 % decrease in waiting-list failures. Patients with hepatocellular-carcinoma were transplanted more often than cirrhotics[at model for end-stage liver-disease (MELD)-15:HR = 1.28,95 %CI:1.21–1.35;at MELD-25:HR = 1.04,95 %CI:0.92–1.19) and those with other indications (at MELD-15:HR = 1.27,95 %CI:1.11–1.46) across all eras. Candidates with Hepatitis-B-virus (HBV)related disease had a greater probability of transplant than those with Hepatitis-C virus-related (HR = 1.13,95 %CI:1.07–1.20), alcohol-related (HR = 1.13,95 %CI:1.05–1.21), and metabolic-related (HR = 1.18,95 %CI:1.09–1.28)disease. Waiting-list failures increased by 27 % every 5 MELD-points and by 14 % for every 5-year increase in recipient-age and decreased by 10 % with each 10-cm increase in stature. Blood-group O patients showed the highest probability of waiting-list failure (HR = 1.28,95 %CI:1.15–1.43).</div></div><div><h3>Conclusions</h3><div>Liver-transplantation waiting-list success-rates have significantly improved in Italy, with patients with hepatocellular-carcinoma and/or HBV-related diseases being favored. High MELD-score, old-age, short-stature, and blood-group O were significant risk-factors for waiting-list failure. Efforts to improve organ-allocation and prioritization-policies are underway.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 2","pages":"Pages 408-416"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low penetrance of frequent ATP7B mutations explains the low prevalence of Wilson disease. Lessons from real-life registries. ATP7B频繁突变的低穿透性解释了威尔逊病发病率低的原因。从实际登记中汲取的教训。
IF 4 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.dld.2024.09.002
Pablo Alonso-Castellano , Antonio Tugores , Zoe Mariño , Antonio Olveira , Marina Berenguer , M. Pilar Huarte , Jose R. Fernández-Ramos , María Lázaro-Ríos , María L. González-Diéguez , José M. Moreno-Planas , Manuel Hernández-Guerra , Paula Fernández-Álvarez , Manuel Delgado-Blanco , José M. Pinazo-Bandera , Marta Romero , Javier Ampuero , Helena Masnou-Ridaura , Alba Cachero , Víctor Vargas , Judith Gómez-Camarero , Luis García-Villarreal

Background & Aims

Wilson disease (WD) is a copper metabolism disorder caused by mutations in ATP7B gene, with significant clinical variability. Several studies have analyzed the prevalence and penetrance of mutations. We evaluated both characteristics for our more frequent mutations.

Methods

Evaluation of 260 patients from the National Registry: clinical, analytical and genetic data. Estimation of homozygotes and total cases according to Hardy-Weinberg equilibrium and comparison with Registry records.

Results

The estimated number of homozygotes were higher than registered: p.Met645Arg (1949/6), p.His1069Gln (20/8), p.Leu708Pro (63/24) and p.Gly869Arg (147/0). p.Met645Arg homozygotes presented less cirrhosis at diagnosis, extrahepatic disease and Kayser-Fleischer ring (KFR) and more presymptomatic cases and diagnosis after 40 years of age than p.Leu708Pro and p.His1069Gln homozygotes. p.Met645Arg homozygotes presented more late diagnosis than p.Met645Arg compound heterozygotes. Compound heterozygotes carrying p.Met645Arg or p.Gly869Arg showed less cirrhosis at diagnosis, KFR and neurological symptoms and more hepatic and presymptomatic cases, despite clearly low ceruloplasmin levels. The estimated prevalence was 1:3.785, predicting more than 10.500 patients.

Conclusions

The widespread mutations p.Met645Arg and p.Gly869Arg show low penetrance. WD might be underdiagnosed in Spain due to less severe phenotype of the most frequent mutations, a crucial fact to avoid misdiagnosis and to offer early therapy.
背景与目的:威尔逊病(WD)是一种由 ATP7B 基因突变引起的铜代谢紊乱疾病,具有显著的临床变异性。一些研究分析了突变的发生率和渗透率。我们对较常见突变的这两个特征进行了评估:方法:评估国家登记处的 260 名患者:临床、分析和遗传数据。根据哈代-温伯格平衡法估算同卵双生者和病例总数,并与登记处的记录进行比较:结果:估计的同卵双生子数量高于登记的数量:p.Met645Arg(1949/6)、p.His1069Gln(20/8)、p.Leu708Pro(63/24)和 p.Gly869Arg(147/0)。与p.Leu708Pro和p.His1069Gln同卵杂合子相比,p.Met645Arg同卵杂合子在确诊时出现肝硬化、肝外疾病和Kayser-Fleischer环(KFR)的情况较少,而无症状病例和40岁以后确诊的病例较多。携带p.Met645Arg或p.Gly869Arg的复合杂合子在诊断时肝硬化、KFR和神经系统症状较少,而肝病和无症状病例较多,尽管ceruloplasmin水平明显较低。估计发病率为1:3.785,预测患者超过10500人:p.Met645Arg和p.Gly869Arg的广泛突变显示出低渗透性。在西班牙,由于最常见突变的表型不太严重,WD 可能诊断不足,这是避免误诊和提供早期治疗的关键所在。
{"title":"Low penetrance of frequent ATP7B mutations explains the low prevalence of Wilson disease. Lessons from real-life registries.","authors":"Pablo Alonso-Castellano ,&nbsp;Antonio Tugores ,&nbsp;Zoe Mariño ,&nbsp;Antonio Olveira ,&nbsp;Marina Berenguer ,&nbsp;M. Pilar Huarte ,&nbsp;Jose R. Fernández-Ramos ,&nbsp;María Lázaro-Ríos ,&nbsp;María L. González-Diéguez ,&nbsp;José M. Moreno-Planas ,&nbsp;Manuel Hernández-Guerra ,&nbsp;Paula Fernández-Álvarez ,&nbsp;Manuel Delgado-Blanco ,&nbsp;José M. Pinazo-Bandera ,&nbsp;Marta Romero ,&nbsp;Javier Ampuero ,&nbsp;Helena Masnou-Ridaura ,&nbsp;Alba Cachero ,&nbsp;Víctor Vargas ,&nbsp;Judith Gómez-Camarero ,&nbsp;Luis García-Villarreal","doi":"10.1016/j.dld.2024.09.002","DOIUrl":"10.1016/j.dld.2024.09.002","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Wilson disease (WD) is a copper metabolism disorder caused by mutations in <em>ATP7B</em> gene, with significant clinical variability. Several studies have analyzed the prevalence and penetrance of mutations. We evaluated both characteristics for our more frequent mutations.</div></div><div><h3>Methods</h3><div>Evaluation of 260 patients from the National Registry: clinical, analytical and genetic data. Estimation of homozygotes and total cases according to Hardy-Weinberg equilibrium and comparison with Registry records.</div></div><div><h3>Results</h3><div>The estimated number of homozygotes were higher than registered: p.Met645Arg (1949/6), p.His1069Gln (20/8), p.Leu708Pro (63/24) and p.Gly869Arg (147/0). p.Met645Arg homozygotes presented less cirrhosis at diagnosis, extrahepatic disease and Kayser-Fleischer ring (KFR) and more presymptomatic cases and diagnosis after 40 years of age than p.Leu708Pro and p.His1069Gln homozygotes. p.Met645Arg homozygotes presented more late diagnosis than p.Met645Arg compound heterozygotes. Compound heterozygotes carrying p.Met645Arg or p.Gly869Arg showed less cirrhosis at diagnosis, KFR and neurological symptoms and more hepatic and presymptomatic cases, despite clearly low ceruloplasmin levels. The estimated prevalence was 1:3.785, predicting more than 10.500 patients.</div></div><div><h3>Conclusions</h3><div>The widespread mutations p.Met645Arg and p.Gly869Arg show low penetrance. WD might be underdiagnosed in Spain due to less severe phenotype of the most frequent mutations, a crucial fact to avoid misdiagnosis and to offer early therapy.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 2","pages":"Pages 443-449"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent trends in foreign body ingestion (FBI) epidemiology: A national cohort study 异物摄入(FBI)流行病学的最新趋势:全国队列研究。
IF 4 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.dld.2024.10.002
Cecilia Mantegazza , Francesca Destro , Simona Ferraro , Davide Biganzoli , Giuseppe Marano , Paolo Quitadamo , Giovanni Di Nardo , Monica Malamisura , Giulia Chiarazzo , Sara Renzo , Luca Scarallo , Giorgio Fava , Martina Ichino , Roberto Panceri , Debora Sala , Maristella Pellegrino , Francesco Macchini , Paolo Gandullia , Giacomo Tantari , Matteo Bramuzzo , Salvatore Oliva

Background and Aims

Foreign body ingestion (FBI) in children is a critical health concern. This study aimed to describe the epidemiology of FBI in children in Italy.

Methods

We retrospectively enrolled children <18 years admitted for FBI from January 2015 to December 2020. Data were collected across 21 hospitals with dedicated pediatric endoscopy services and normalized by the population of the corresponding municipalities.

Results

A total of 5,771 FBI cases were analyzed. FBI incidents showed consistent time trends across age groups, with most events occurring at home and being witnessed (94.7 %). Children <6 years accounted for 74.3 % of cases. Comorbidities were present in 5.3 % of cases, primarily neurologic/psychiatric disorders in older children (6–17 years). Blunt objects accounted for 65.5 % of ingestions. Young males commonly ingested button batteries, while females showed higher rates of ingesting hair products and jewelry. Most children were discharged (60 %) or observed briefly (75 % of total admissions), with endoscopic removal performed in 24 % of cases.

Conclusions

Rates of FBI have remained stable over the years, including during the COVID-19 pandemic. FBI predominantly occurs in domestic settings among healthy young children, particularly those ≤5 years old. These findings emphasize the need for preventive measures to reduce the impact of FBI among children.
背景和目的:儿童异物摄入(FBI)是一个严重的健康问题。本研究旨在描述意大利儿童异物误食的流行病学:我们对儿童进行了回顾性登记:结果:共分析了 5771 例 FBI 病例。各年龄组的联邦调查局事件呈现出一致的时间趋势,大多数事件发生在家中并有人目击(94.7%)。儿童 结论:多年来,包括在 COVID-19 大流行期间,FBI 的发生率一直保持稳定。FBI 主要发生在家庭环境中的健康幼儿,尤其是 5 岁以下的幼儿。这些发现强调有必要采取预防措施,以减少联邦调查局对儿童的影响。
{"title":"Recent trends in foreign body ingestion (FBI) epidemiology: A national cohort study","authors":"Cecilia Mantegazza ,&nbsp;Francesca Destro ,&nbsp;Simona Ferraro ,&nbsp;Davide Biganzoli ,&nbsp;Giuseppe Marano ,&nbsp;Paolo Quitadamo ,&nbsp;Giovanni Di Nardo ,&nbsp;Monica Malamisura ,&nbsp;Giulia Chiarazzo ,&nbsp;Sara Renzo ,&nbsp;Luca Scarallo ,&nbsp;Giorgio Fava ,&nbsp;Martina Ichino ,&nbsp;Roberto Panceri ,&nbsp;Debora Sala ,&nbsp;Maristella Pellegrino ,&nbsp;Francesco Macchini ,&nbsp;Paolo Gandullia ,&nbsp;Giacomo Tantari ,&nbsp;Matteo Bramuzzo ,&nbsp;Salvatore Oliva","doi":"10.1016/j.dld.2024.10.002","DOIUrl":"10.1016/j.dld.2024.10.002","url":null,"abstract":"<div><h3>Background and Aims</h3><div>Foreign body ingestion (FBI) in children is a critical health concern. This study aimed to describe the epidemiology of FBI in children in Italy.</div></div><div><h3>Methods</h3><div>We retrospectively enrolled children &lt;18 years admitted for FBI from January 2015 to December 2020. Data were collected across 21 hospitals with dedicated pediatric endoscopy services and normalized by the population of the corresponding municipalities.</div></div><div><h3>Results</h3><div>A total of 5,771 FBI cases were analyzed. FBI incidents showed consistent time trends across age groups, with most events occurring at home and being witnessed (94.7 %). Children &lt;6 years accounted for 74.3 % of cases. Comorbidities were present in 5.3 % of cases, primarily neurologic/psychiatric disorders in older children (6–17 years). Blunt objects accounted for 65.5 % of ingestions. Young males commonly ingested button batteries, while females showed higher rates of ingesting hair products and jewelry. Most children were discharged (60 %) or observed briefly (75 % of total admissions), with endoscopic removal performed in 24 % of cases.</div></div><div><h3>Conclusions</h3><div>Rates of FBI have remained stable over the years, including during the COVID-19 pandemic. FBI predominantly occurs in domestic settings among healthy young children, particularly those ≤5 years old. These findings emphasize the need for preventive measures to reduce the impact of FBI among children.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 2","pages":"Pages 595-602"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142544243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antibiotic usage within the first year of life has a protective effect against ulcerative colitis in South Korea: A nationwide cohort study 在韩国,婴儿出生后第一年内使用抗生素对溃疡性结肠炎有保护作用:一项全国性队列研究。
IF 4 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.dld.2024.10.016
Junseok Park , Sungjin Woo , Young-Geun Choi , Hoyoung Park , Jong Pil Im , Hyun Jung Lee , Joo Sung Kim , Yoo Min Han , Hyunsun Park , Seong-Joon Koh

Background

Antibiotic usage in early life has been proposed as a risk factor for inflammatory bowel disease, especially Crohn's disease. However, most studies were conducted in Western countries.

Aims

We evaluated the association between antibiotic usage and the incidence of inflammatory bowel disease in the Asian population.

Methods

This nationwide population-based retrospective cohort study included 2,941,889 South Korean infants born between 2007 and 2015, using the National Health Insurance Service database. We assessed whether antibiotic use was associated with the incidence of inflammatory bowel disease. Additionally, we conducted sensitivity analyses, considering protopathic bias and dietary variables. The Cox proportional hazards model was used.

Results

Among 2,941,889 infants, 2,566,390 (87 %) used antibiotics within a year after birth. Antibiotic usage within a year, number of antibiotic classes, and cumulative days of usage were shown to decrease the risk of ulcerative colitis. This association was particularly prominent with earlier antibiotic exposure. Penicillin was the only antibiotic class related to the reduced risk. The results were robust after adjusting for dietary variables and considering protopathic effect.

Conclusions

Antibiotic exposure during the first year of life, particularly at a younger age, is linked to a reduced risk of early-onset ulcerative colitis in South Korea.
背景:早年使用抗生素被认为是炎症性肠病,尤其是克罗恩病的风险因素。目的:我们评估了亚洲人使用抗生素与炎症性肠病发病率之间的关系:这项基于全国人口的回顾性队列研究利用国民健康保险服务数据库,纳入了 2,941,889 名在 2007 年至 2015 年间出生的韩国婴儿。我们评估了抗生素的使用是否与炎症性肠病的发病率有关。此外,我们还进行了敏感性分析,考虑了原发病偏倚和饮食变量。我们使用了 Cox 比例危险模型:在 2,941,889 名婴儿中,有 2,566,390 名婴儿(87%)在出生后一年内使用过抗生素。结果表明,一年内使用抗生素、抗生素种类的数量和累计使用天数会降低溃疡性结肠炎的风险。这种关联在较早接触抗生素时尤为突出。青霉素是唯一与降低风险有关的抗生素类别。在对饮食变量进行调整并考虑原发病效应后,研究结果仍很可靠:结论:在韩国,出生后第一年接触抗生素,尤其是在较小的年龄接触抗生素,与降低早发溃疡性结肠炎的风险有关。
{"title":"Antibiotic usage within the first year of life has a protective effect against ulcerative colitis in South Korea: A nationwide cohort study","authors":"Junseok Park ,&nbsp;Sungjin Woo ,&nbsp;Young-Geun Choi ,&nbsp;Hoyoung Park ,&nbsp;Jong Pil Im ,&nbsp;Hyun Jung Lee ,&nbsp;Joo Sung Kim ,&nbsp;Yoo Min Han ,&nbsp;Hyunsun Park ,&nbsp;Seong-Joon Koh","doi":"10.1016/j.dld.2024.10.016","DOIUrl":"10.1016/j.dld.2024.10.016","url":null,"abstract":"<div><h3>Background</h3><div>Antibiotic usage in early life has been proposed as a risk factor for inflammatory bowel disease, especially Crohn's disease. However, most studies were conducted in Western countries.</div></div><div><h3>Aims</h3><div>We evaluated the association between antibiotic usage and the incidence of inflammatory bowel disease in the Asian population.</div></div><div><h3>Methods</h3><div>This nationwide population-based retrospective cohort study included 2,941,889 South Korean infants born between 2007 and 2015, using the National Health Insurance Service database. We assessed whether antibiotic use was associated with the incidence of inflammatory bowel disease. Additionally, we conducted sensitivity analyses, considering protopathic bias and dietary variables. The Cox proportional hazards model was used.</div></div><div><h3>Results</h3><div>Among 2,941,889 infants, 2,566,390 (87 %) used antibiotics within a year after birth. Antibiotic usage within a year, number of antibiotic classes, and cumulative days of usage were shown to decrease the risk of ulcerative colitis. This association was particularly prominent with earlier antibiotic exposure. Penicillin was the only antibiotic class related to the reduced risk. The results were robust after adjusting for dietary variables and considering protopathic effect.</div></div><div><h3>Conclusions</h3><div>Antibiotic exposure during the first year of life, particularly at a younger age, is linked to a reduced risk of early-onset ulcerative colitis in South Korea.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 2","pages":"Pages 616-623"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142616668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mannitol for bowel preparation: Efficacy and safety results from the SATISFACTION randomised clinical trial 用于肠道准备的甘露醇:SATISFACTION 随机临床试验的疗效和安全性结果。
IF 4 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.dld.2024.09.024
Maurizio Vecchi , Gian Eugenio Tontini , Giancarla Fiori , Paolo Bocus , Marino Carnovali , Paola Cesaro , Guido Costamagna , Dhanai Di Paolo , Luca Elli , Olga Fedorishina , Carsten Hinkel , Ralf Jakobs , Sergey Kashin , Michela Magnoli , Gianpiero Manes , Ekaterina Melnikova , Anna Orsatti , Thierry Ponchon , Alberto Prada , Franco Radaelli , Tim ZIMMERMANN

Background

Bowel preparation represents a significant issue to high-quality colonoscopy. Oral mannitol requires a single dose, is of low volume, and has a pleasant taste and rapid action.

Aims

This SATISFACTION study compared single-dose (same day) oral mannitol 100 g/750 mL with standard split-dose PEG-ASC2 L (MoviPrep®).

Methods

The primary endpoint was the proportion of patients with adequate bowel cleansing. Secondary endpoints included efficacy (adenoma detection rate, caecal intubation rate, time of evacuation), safety (intestinal gases concentration, haemato-chemical parameters, adverse events), and patient satisfaction.

Results

The study included 703 patients (352 treated with mannitol and 351 with PEG-ASC). Mannitol was not inferior to PEG-ASC for the primary endpoint (91.1 % and 95.5 %, respectively; p-value for the non-inferiority =0.0131). There was no significant difference for secondary efficacy endpoints. The acceptability profile was significantly better in the mannitol group for ease of use, taste, and willingness to reuse (p < 0.0001 for all). The concentration of intestinal gases (H2, CH4) was similar between groups and well below those potentially critical.

Conclusions

The SATISFACTION study indicated that low-volume, single-dose mannitol may satisfy an unmet clinical need since it was more acceptable to the patient and not inferior to the split-dose PEG-ASC for bowel cleansing efficacy.
背景:肠道准备是高质量结肠镜检查的一个重要问题。目的:这项 SATISFACTION 研究比较了单剂量(当天)口服甘露醇 100 克/750 毫升和标准分剂量 PEG-ASC2 L(MoviPrep®):主要终点是充分清洁肠道的患者比例。次要终点包括疗效(腺瘤检出率、盲肠插管率、排空时间)、安全性(肠道气体浓度、血液化学参数、不良事件)和患者满意度:研究包括 703 名患者(其中 352 人接受甘露醇治疗,351 人接受 PEG-ASC 治疗)。就主要终点而言,甘露醇的疗效不逊于 PEG-ASC(分别为 91.1% 和 95.5%;非劣效性的 p 值 =0.0131)。次要疗效终点无明显差异。在易用性、口感和重复使用意愿方面,甘露醇组的可接受性明显更好(均为 p <0.0001)。各组的肠道气体(H2、CH4)浓度相似,远低于潜在的临界值:SATISFACTION 研究表明,小剂量、单剂量甘露醇可以满足尚未满足的临床需求,因为它更容易被患者接受,而且在肠道清洁效果方面并不比分剂量 PEG-ASC 差。
{"title":"Mannitol for bowel preparation: Efficacy and safety results from the SATISFACTION randomised clinical trial","authors":"Maurizio Vecchi ,&nbsp;Gian Eugenio Tontini ,&nbsp;Giancarla Fiori ,&nbsp;Paolo Bocus ,&nbsp;Marino Carnovali ,&nbsp;Paola Cesaro ,&nbsp;Guido Costamagna ,&nbsp;Dhanai Di Paolo ,&nbsp;Luca Elli ,&nbsp;Olga Fedorishina ,&nbsp;Carsten Hinkel ,&nbsp;Ralf Jakobs ,&nbsp;Sergey Kashin ,&nbsp;Michela Magnoli ,&nbsp;Gianpiero Manes ,&nbsp;Ekaterina Melnikova ,&nbsp;Anna Orsatti ,&nbsp;Thierry Ponchon ,&nbsp;Alberto Prada ,&nbsp;Franco Radaelli ,&nbsp;Tim ZIMMERMANN","doi":"10.1016/j.dld.2024.09.024","DOIUrl":"10.1016/j.dld.2024.09.024","url":null,"abstract":"<div><h3>Background</h3><div>Bowel preparation represents a significant issue to high-quality colonoscopy. Oral mannitol requires a single dose, is of low volume, and has a pleasant taste and rapid action.</div></div><div><h3>Aims</h3><div>This SATISFACTION study compared single-dose (same day) oral mannitol 100 g/750 mL with standard split-dose PEG-ASC2 L (MoviPrep®).</div></div><div><h3>Methods</h3><div>The primary endpoint was the proportion of patients with adequate bowel cleansing. Secondary endpoints included efficacy (adenoma detection rate, caecal intubation rate, time of evacuation), safety (intestinal gases concentration, haemato-chemical parameters, adverse events), and patient satisfaction.</div></div><div><h3>Results</h3><div>The study included 703 patients (352 treated with mannitol and 351 with PEG-ASC). Mannitol was not inferior to PEG-ASC for the primary endpoint (91.1 % and 95.5 %, respectively; p-value for the non-inferiority =0.0131). There was no significant difference for secondary efficacy endpoints. The acceptability profile was significantly better in the mannitol group for ease of use, taste, and willingness to reuse (<em>p</em> &lt; 0.0001 for all). The concentration of intestinal gases (H<sub>2</sub>, CH<sub>4</sub>) was similar between groups and well below those potentially critical.</div></div><div><h3>Conclusions</h3><div>The SATISFACTION study indicated that low-volume, single-dose mannitol may satisfy an unmet clinical need since it was more acceptable to the patient and not inferior to the split-dose PEG-ASC for bowel cleansing efficacy.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 2","pages":"Pages 574-583"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142675118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Author's reply: “Are early-life exposures associated with inflammatory bowel disease? A critique of a recent nested case-control study” 作者回复:"早期生活暴露与炎症性肠病有关吗?对最近一项巢式病例对照研究的评论"。
IF 4 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.dld.2024.11.024
Canisius Fantodji , Marie-Claude Rousseau , Belinda Nicolau , Sreenath Madathil , Andrea Benedetti , Prévost Jantchou
{"title":"Author's reply: “Are early-life exposures associated with inflammatory bowel disease? A critique of a recent nested case-control study”","authors":"Canisius Fantodji ,&nbsp;Marie-Claude Rousseau ,&nbsp;Belinda Nicolau ,&nbsp;Sreenath Madathil ,&nbsp;Andrea Benedetti ,&nbsp;Prévost Jantchou","doi":"10.1016/j.dld.2024.11.024","DOIUrl":"10.1016/j.dld.2024.11.024","url":null,"abstract":"","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 2","pages":"Pages 645-646"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142823994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of magnetic resonance enterography for children with Crohn's disease: A multicenter, multireader study 儿童克罗恩病磁共振肠造影的预后价值:一项多中心、多阅读器研究。
IF 4 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.dld.2024.11.011
Anastasiia Romanchuk , Clarissa Valle , Arianna Ghirardi , Pietro Andrea Bonaffini , Davide Ippolito , Naire Sansotta , Margherita Calia , Giovanna Zuin , Paolo Marra , Lorenzo D'Antiga , Lorenzo Norsa

Background

Paediatric Inflammatory Crohn's MRE Index (PICMI) is a multi-point index of intestinal inflammation (mucosal and transmural) for children with CD. The present study aims to assess whether PICMI at diagnosis may predict the course of CD and to test the inter-reader agreement.

Methods

CD children with a ≥ 1-year follow-up were retrospectively enrolled. Three radiologists calculated PICMI at diagnosis and association between PICMI and Paediatric Crohn's Disease Activity Index (PCDAI) and CD Endoscopic Index of Severity (CDEIS) was tested.

Results

68 children (median age 13 years IQR: 11–14) with CD with PICMI at diagnosis: remission 6 (8.8 %), mild 29 (42.6 %), moderate 24 (35.3 %), severe 9 (13.2 %), were enrolled. PICMI score significantly correlated with PCDAI at diagnosis (p: 0.036). Steroid-free remission at 1, 3 and 5 years was comparable between PICMI groups (p: 0.606). Higher PICMI at diagnosis was associated with higher biologic introduction at 1 year: incidence rate ratio IRR: 2.17 (1.09–4.42); p = 0.019, 3-year IRR: 2.12 (1.15–3.96); p = 0.011, and 5 years: 2.21 (1.20–4.08); p = 0.007.

Conclusions

PICMI score is a reliable and almost reproducible index to score activity in children with CD. Children with higher PICMI scores of disease activity at diagnosis required more biologic treatment to achieve comparable rates of steroid-free remission if compared with lower PICMI scores.
背景:儿童炎症性克罗恩MRE指数(PICMI)是一个多点肠炎症(粘膜和跨壁)指数,用于诊断CD的儿童。本研究旨在评估PICMI是否可以预测CD的病程,并测试读者间的一致性。方法:回顾性纳入随访≥1年的CD患儿。三名放射科医生计算诊断时的PICMI,并测试PICMI与儿科克罗恩病活动性指数(PCDAI)和CD内窥镜严重程度指数(CDEIS)之间的关系。结果:68名诊断时患有CD并PICMI的儿童(中位年龄13岁IQR: 11-14):缓解6名(8.8%),轻度29名(42.6%),中度24名(35.3%),重度9名(13.2%)。PICMI评分与诊断时PCDAI有显著相关性(p: 0.036)。PICMI组间1年、3年和5年无类固醇缓解具有可比性(p: 0.606)。诊断时较高的PICMI与1年后较高的生物引入相关:发病率比IRR: 2.17 (1.09-4.42);p = 0.019, 3年IRR: 2.12 (1.15-3.96);P = 0.011, 5年:2.21 (1.20-4.08);P = 0.007。结论:PICMI评分是一种可靠且几乎可重复的CD患儿活动性评分指标。与PICMI评分较低的儿童相比,诊断时疾病活动性PICMI评分较高的儿童需要更多的生物治疗以达到可比的无类固醇缓解率。
{"title":"Prognostic value of magnetic resonance enterography for children with Crohn's disease: A multicenter, multireader study","authors":"Anastasiia Romanchuk ,&nbsp;Clarissa Valle ,&nbsp;Arianna Ghirardi ,&nbsp;Pietro Andrea Bonaffini ,&nbsp;Davide Ippolito ,&nbsp;Naire Sansotta ,&nbsp;Margherita Calia ,&nbsp;Giovanna Zuin ,&nbsp;Paolo Marra ,&nbsp;Lorenzo D'Antiga ,&nbsp;Lorenzo Norsa","doi":"10.1016/j.dld.2024.11.011","DOIUrl":"10.1016/j.dld.2024.11.011","url":null,"abstract":"<div><h3>Background</h3><div>Paediatric Inflammatory Crohn's MRE Index (PICMI) is a multi-point index of intestinal inflammation (mucosal and transmural) for children with CD. The present study aims to assess whether PICMI at diagnosis may predict the course of CD and to test the inter-reader agreement.</div></div><div><h3>Methods</h3><div>CD children with <em>a</em> ≥ 1-year follow-up were retrospectively enrolled. Three radiologists calculated PICMI at diagnosis and association between PICMI and Paediatric Crohn's Disease Activity Index (PCDAI) and CD Endoscopic Index of Severity (CDEIS) was tested.</div></div><div><h3>Results</h3><div>68 children (median age 13 years IQR: 11–14) with CD with PICMI at diagnosis: remission 6 (8.8 %), mild 29 (42.6 %), moderate 24 (35.3 %), severe 9 (13.2 %), were enrolled. PICMI score significantly correlated with PCDAI at diagnosis (p: 0.036). Steroid-free remission at 1, 3 and 5 years was comparable between PICMI groups (p: 0.606). Higher PICMI at diagnosis was associated with higher biologic introduction at 1 year: incidence rate ratio IRR: 2.17 (1.09–4.42); <em>p</em> = 0.019, 3-year IRR: 2.12 (1.15–3.96); <em>p</em> = 0.011, and 5 years: 2.21 (1.20–4.08); <em>p</em> = 0.007.</div></div><div><h3>Conclusions</h3><div>PICMI score is a reliable and almost reproducible index to score activity in children with CD. Children with higher PICMI scores of disease activity at diagnosis required more biologic treatment to achieve comparable rates of steroid-free remission if compared with lower PICMI scores.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 2","pages":"Pages 624-629"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatitis E virus infection in immunosuppressed patients and its clinical manifestations 免疫抑制患者的戊型肝炎病毒感染及其临床表现。
IF 4 3区 医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2025-02-01 DOI: 10.1016/j.dld.2024.06.020
Paul Kupke , Maximilian Kupke , Stefan Borgmann , Arne Kandulski , Florian Hitzenbichler , Josef Menzel , Edward K. Geissler , Hans J. Schlitt , Jürgen J. Wenzel , Jens M. Werner

Background & Aims

Hepatitis E virus (HEV) is a main cause of acute hepatitis globally. However, immunosuppressed patients regularly develop chronic courses. The aim of this study was to analyse the current status of HEV diagnostics, characterize clinical manifestations and identify risk factors for complicated HEV infections.

Methods

In this retrospective study at two large hospitals, 512 patients with borderline and positive anti-HEV-IgM and 94 patients with positive HEV-PCR between January 1999 and May 2023 were included.

Results

Detection by anti-HEV-IgM-ELISA led to a positive HEV-PCR in only 17.9 %. Amongst patients with positive HEV-PCR, 61 had underlying immunosuppression and 23 were patients after solid organ transplantation (SOT). All 13 patients with chronic HEV infections were immunosuppressed. Generally, immunosuppression led to higher HEV-RNA concentrations and a higher probability of receiving immediate treatment. However, all fulminant courses with liver failure happened in patients without immunosuppression. Immunocompetent patients showed symptoms more frequently and primarily had higher bilirubin levels indicating more severe liver damage. A risk factor for delayed or failed viral clearance after SOT was the administration of mTOR inhibitors.

Conclusions

Fulminant HEV infections happen primarily in immunocompetent patients. Nevertheless, immunosuppressed patients bear the risk of undetected, prolonged HEV infections, reflected by the rare occurrence of symptoms.
背景与目的:戊型肝炎病毒(HEV)是全球急性肝炎的主要病因。然而,免疫抑制患者也会定期出现慢性病程。本研究旨在分析戊型肝炎病毒诊断的现状、临床表现的特征,并确定戊型肝炎病毒感染并发症的风险因素:在两家大型医院进行的这项回顾性研究中,纳入了 1999 年 1 月至 2023 年 5 月间 512 例抗 HEV-IgM 阴性和阳性患者以及 94 例 HEV-PCR 阳性患者:结果:抗-HEV-IgM-ELISA 检测导致 HEV-PCR 阳性的比例仅为 17.9%。在 HEV-PCR 阳性的患者中,61 人有潜在的免疫抑制,23 人是实体器官移植 (SOT) 后的患者。13 名慢性 HEV 感染患者均有免疫抑制。一般来说,免疫抑制会导致 HEV-RNA 浓度升高,并增加立即接受治疗的几率。然而,所有伴有肝功能衰竭的急性病程都发生在没有免疫抑制的患者身上。免疫功能正常的患者出现症状的频率更高,主要是胆红素水平更高,表明肝损伤更严重。SOT后病毒清除延迟或失败的一个风险因素是使用mTOR抑制剂:结论:恶性 HEV 感染主要发生在免疫功能正常的患者身上。尽管如此,免疫抑制患者仍有可能发生未被发现的、持续时间较长的 HEV 感染,这一点从极少出现症状中可见一斑。
{"title":"Hepatitis E virus infection in immunosuppressed patients and its clinical manifestations","authors":"Paul Kupke ,&nbsp;Maximilian Kupke ,&nbsp;Stefan Borgmann ,&nbsp;Arne Kandulski ,&nbsp;Florian Hitzenbichler ,&nbsp;Josef Menzel ,&nbsp;Edward K. Geissler ,&nbsp;Hans J. Schlitt ,&nbsp;Jürgen J. Wenzel ,&nbsp;Jens M. Werner","doi":"10.1016/j.dld.2024.06.020","DOIUrl":"10.1016/j.dld.2024.06.020","url":null,"abstract":"<div><h3>Background &amp; Aims</h3><div>Hepatitis E virus (HEV) is a main cause of acute hepatitis globally. However, immunosuppressed patients regularly develop chronic courses. The aim of this study was to analyse the current status of HEV diagnostics, characterize clinical manifestations and identify risk factors for complicated HEV infections.</div></div><div><h3>Methods</h3><div>In this retrospective study at two large hospitals, 512 patients with borderline and positive anti-HEV-IgM and 94 patients with positive HEV-PCR between January 1999 and May 2023 were included.</div></div><div><h3>Results</h3><div>Detection by anti-HEV-IgM-ELISA led to a positive HEV-PCR in only 17.9 %. Amongst patients with positive HEV-PCR, 61 had underlying immunosuppression and 23 were patients after solid organ transplantation (SOT). All 13 patients with chronic HEV infections were immunosuppressed. Generally, immunosuppression led to higher HEV-RNA concentrations and a higher probability of receiving immediate treatment. However, all fulminant courses with liver failure happened in patients without immunosuppression. Immunocompetent patients showed symptoms more frequently and primarily had higher bilirubin levels indicating more severe liver damage. A risk factor for delayed or failed viral clearance after SOT was the administration of mTOR inhibitors.</div></div><div><h3>Conclusions</h3><div>Fulminant HEV infections happen primarily in immunocompetent patients. Nevertheless, immunosuppressed patients bear the risk of undetected, prolonged HEV infections, reflected by the rare occurrence of symptoms.</div></div>","PeriodicalId":11268,"journal":{"name":"Digestive and Liver Disease","volume":"57 2","pages":"Pages 378-384"},"PeriodicalIF":4.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141598887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Digestive and Liver Disease
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1